Patents Assigned to INBIOMOTION S.L.
-
Patent number: 11892453Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which, comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.Type: GrantFiled: June 4, 2021Date of Patent: February 6, 2024Assignee: INBIOMOTION S.L.Inventors: Roger Gomis, Joël Jean-Mairet
-
Patent number: 11840740Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.Type: GrantFiled: June 21, 2021Date of Patent: December 12, 2023Assignee: INBIOMOTION S.L.Inventors: Roger Gomis, Joël Jean-Mairet
-
Patent number: 11654153Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.Type: GrantFiled: November 21, 2018Date of Patent: May 23, 2023Assignee: INBIOMOTION S.L.Inventors: Walter Martin Gregory, Juan Carlos Tercero, Robert E. Coleman, Roger Gomis
-
Patent number: 11596642Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid.Type: GrantFiled: May 25, 2017Date of Patent: March 7, 2023Assignee: INBIOMOTION S.L.Inventors: Walter Martin Gregory, Juan Carlos Tercero, Roger Gomis, Robert E. Coleman
-
Patent number: 11041213Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.Type: GrantFiled: September 26, 2018Date of Patent: June 22, 2021Assignee: INBIOMOTION S.L.Inventors: Roger Gomis, Joël Jean-Mairet
-
Patent number: 11041861Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which, comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.Type: GrantFiled: September 18, 2018Date of Patent: June 22, 2021Assignee: INBIOMOTION S.L.Inventors: Roger Gomis, Joël Jean-Mairet
-
Patent number: 10793642Abstract: The disclosure relates to binding members, especially antibody molecules, which bind to human Maf. The binding members are useful for the determination of the expression level of Maf.Type: GrantFiled: December 11, 2015Date of Patent: October 6, 2020Assignee: INBIOMOTION S.L.Inventors: Roger Gomis, Juan Carlos Tercero
-
Publication number: 20190269707Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid.Type: ApplicationFiled: May 25, 2017Publication date: September 5, 2019Applicant: INBIOMOTION S.L.Inventors: Walter Martin GREGORY, Juan Carlos TERCERO, Roger GOMIS, Robert E. COLEMAN
-
Patent number: 10119171Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.Type: GrantFiled: June 15, 2016Date of Patent: November 6, 2018Assignee: InBioMotion S.L.Inventors: Roger Gomis, Joël Jean-Mairet
-
Patent number: 10114022Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which, comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.Type: GrantFiled: October 9, 2013Date of Patent: October 30, 2018Assignee: INBIOMOTION S.L.Inventors: Roger Gomis, Joël Jean-Mairet
-
Publication number: 20170369589Abstract: The disclosure relates to binding members, especially antibody molecules, which bind to human Maf. The binding members are useful for the determination of the expression level of Maf.Type: ApplicationFiled: December 11, 2015Publication date: December 28, 2017Applicant: INBIOMOTION S.L.Inventors: Roger GOMIS, Juan Carlos TERCERO
-
Publication number: 20160032399Abstract: The present invention relates to a method for the prognosis of bone metastasis in renal cell carcinoma which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering renal cell carcinoma. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of renal cell carcinoma metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering renal cell carcinoma and for classifying a subject from renal cell carcinoma into a cohort.Type: ApplicationFiled: March 13, 2014Publication date: February 4, 2016Applicant: INBIOMOTION S.L.Inventors: Roger GOMIS, David L. LACEY
-
Publication number: 20150362495Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which, comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.Type: ApplicationFiled: October 9, 2013Publication date: December 17, 2015Applicant: INBIOMOTION S.L.Inventors: Roger GOMIS, Joel JEAN-MAIRET